SHANGHAI, China, Aug. 1 /Xinhua-PRNewswire/ - -- - WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it has appointed Mr. Steven M. Hutchins as Vice President of Business Development.
Prior to joining WuXi PharmaTech, Mr. Hutchins was Vice President of Business Development & Collaboration Management at BioDuro, a U.S.-based life science outsourcing service company, and earlier Senior Director of Global Basic and PreClinical Sourcing at Merck.
Mr. Hutchins will be responsible for leading the company's global business development and reinforcing WuXi's brand value and market leadership. Mr. Hutchins will report directly to Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.
"It was a great pleasure that I had the opportunity to manage the collaboration between WuXi and Merck in the past six years, and help to grow the relationship into a strategic long-term partnership. I am very excited to join WuXi, the best CRO company among those I am aware of in North America, Europe, China and India," said Mr. Hutchins.
"I am very pleased to welcome Steven on board. Steven's intimate knowledge of CROs and deep understanding of pharmaceutical R&D outsourcing needs will help WuXi to continue the strong business growth," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
Mr. Hutchins received his B.S. in Chemistry from University of New Hampshire, New Hampshire.
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical
device R&D outsourcing company, with operations in China and the United
States. As a research-driven and customer-focused company, WuXi PharmaTech
provides pharmaceutical, biotechnology and medical device companies a broad
and integrated portfolio of laboratory and manufacturing services
throughout the drug and medical device R&D process. WuXi PharmaTech's
services are designed to assist its global partners in shortening the cycle
and lowering the cost of drug and medical device R&D. For more information,
please visit: http://www.wuxipharmatech.com .
For more information, please contact:
|SOURCE WuXi PharmaTech (Cayman) Inc.|
Copyright©2008 PR Newswire.
All rights reserved